# Retatrutide Research: Mechanism, Trial Data, and Phase 3 — Medicine Retatrutide > Retatrutide Phase 2 and Phase 3 trial data — triple-agonist mechanism, cryo-EM structure, obesity and MASLD outcomes, and the TRIUMPH program. Cited from published literature. Structural pharmacology, obesity and diabetes trial outcomes, liver-fat data, and ongoing Phase 3 trials — cited to primary sources. ## The research record at a glance Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. It is an investigational drug — not approved by any regulator — currently in the Phase 3 TRIUMPH clinical program. The compound is the subject of multiple published Phase 1 and Phase 2 trials and several recent systematic reviews. The key pharmacological feature is simultaneous activation of three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide receptor), GLP-1 receptor, and glucagon receptor (GCGR). Earlier incretin agents act on one or two of these; retatrutide acts on all three in a single molecule. Phase 2 data established: approximately 24% body-weight reduction in obesity at 48 weeks [1]; HbA1c reduction of 2.02% in type 2 diabetes at 24 weeks [2]; liver-fat reduction of 82.4% in MASLD at 24 weeks [5]; a plasma half-life of approximately 6 days [4]. Phase 3 trials (obesity, diabetes, cardiovascular, kidney) are ongoing. No approval exists as of 2026. ## Triple-agonist mechanism and structural pharmacology The mechanism of retatrutide rests on three receptor axes. **GLP-1 receptor (GLP-1R).** GLP-1 (glucagon-like peptide-1) is an incretin hormone — a gut-derived signal that amplifies insulin secretion after eating. GLP-1R activation suppresses appetite, slows gastric emptying, and promotes glucose-dependent insulin release. This is the axis shared with the single-agonist agents already in clinical use for obesity and diabetes. **GIP receptor (GIPR).** GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone. GIPR activation enhances postprandial (after-meal) insulin secretion and has direct effects on adipose (fat) tissue. Cryo-EM structural work (Li et al., *Cell Discovery*, 2024) showed retatrutide is approximately 8.9× more potent at GIPR than native GIP, despite a GIP-based backbone [3]. The high GIPR potency is engineered by the C20 fatty-diacid acylation that binds the peptide to albumin for extended half-life — the same structural feature that produces prolonged plasma residence. **Glucagon receptor (GCGR).** Glucagon is a pancreatic hormone that raises blood glucose and increases energy expenditure by stimulating hepatic (liver) fat breakdown. Selective GCGR activation in isolation would raise blood glucose — harmful in metabolic disease. In retatrutide, the GLP-1/GIP arms provide insulin-secretion counterbalance, allowing GCGR's energy-expenditure signal to operate without net hyperglycemia. The cryo-EM study found retatrutide is 0.3× as potent at GCGR as native glucagon — a deliberate attenuation that preserves the thermogenic benefit while limiting glucagonergic side effects [3]. The three arms signal through cAMP/PKA (cyclic AMP / protein kinase A — a standard intracellular signaling cascade used by hormones to translate an extracellular signal into a cellular response) downstream of all three class-B GPCRs. The triple cAMP signal is additive, which researchers believe underpins the efficacy step-change versus dual or single agonists [6]. A 2025 review (Drucker DJ et al., *Diabetes Care*) noted that retatrutide and similar new molecular entities exhibit unique PK/PD (pharmacokinetic/pharmacodynamic — how the drug moves through the body and what it does) profiles compared with first-generation GLP-1 agents, reflecting simultaneous glucagon and GLP-1 activation [8]. ## Phase 2 clinical outcomes **Obesity (Jastreboff et al., NEJM, 2023).** 338 adults with BMI ≥30 or ≥27 plus comorbidity received once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg over 48 weeks. At 12 mg, mean body-weight change was −24.2% versus −2.1% with placebo. GI adverse events were dose-related and predominantly mild-to-moderate. A dose-dependent heart-rate increase peaked at approximately week 24 [1]. **Type 2 diabetes (Rosenstock et al., Lancet, 2023).** 281 adults received once-weekly retatrutide 0.5–12 mg with stepwise dose escalation. At 12 mg and 24 weeks: HbA1c −2.02% (placebo −0.01%); body weight −16.94% at 36 weeks (placebo −3.00%). Mild-to-moderate GI adverse events in 35% of participants; no severe hypoglycemia; no deaths [2]. **MASLD substudy (Sanyal et al., Nature Medicine, 2024).** 98 participants with ≥10% liver fat by MRI-PDFF and no type 2 diabetes. Retatrutide 12 mg: relative liver-fat change −82.4% at 24 weeks (placebo +0.3%); 86% reached normal liver fat (<5%) at 24 weeks; reduction sustained to −86.0% at 48 weeks [5]. **Phase 1b first-in-human pharmacokinetics (Urva et al., Lancet, 2022).** 72 adults with type 2 diabetes received single/multiple ascending doses. Half-life approximately 6 days. Placebo-adjusted weight loss −8.96 kg (90% CI −11.16 to −6.75) at highest dose over 12 weeks. Treatment-emergent adverse events in 63%, mostly GI; acceptable safety profile [4]. **Retatrutide results summary**: across the Phase 2 program, the compound reduced body weight, HbA1c, and liver fat in three separate randomized controlled trials — the strongest clinical evidence package any investigational incretin agent has assembled to date. ## Phase 3 TRIUMPH program The ongoing Phase 3 program is designated TRIUMPH. Trials include: - **TRIUMPH-1 and TRIUMPH-2**: obesity (BMI ≥30) without and with type 2 diabetes - **TRIUMPH-3**: obesity with established cardiovascular disease - **Cardiovascular outcomes (NCT06383390)**: dedicated MACE (major adverse cardiovascular event) endpoint study - **Kidney outcomes (TRANSCEND-CKD, NCT05929066)**: chronic kidney disease population - **CKD-related metabolic endpoints (NCT05931367)** - **Additional endpoints (NCT05882045)** - **Active comparator vs tirzepatide** (a dual GIP/GLP-1 agonist) A 2025 systematic review of 53 phase 2 and 3 obesity trials confirmed retatrutide among 14 agents in active phase 3 programs [11]. A 2025 pipeline review (Madsbad et al., *Expert Opinion on Investigational Drugs*) identified slow up-titration as the key strategy for managing GI adverse-event burden in the class, with retatrutide's phase 3 design incorporating this learning [12]. A comprehensive 2026 overview (Panou et al., *Expert Review of Clinical Pharmacology*) reported efficacy figures from the full Phase 2 dataset: HbA1c reduction up to 2.16%, weight loss up to 26.56%, with GI event rates linked to the escalation rate and starting dose [15]. The long-term cardiovascular and renal outcomes remain outstanding. ## Retatrutide vs tirzepatide Tirzepatide is a dual GIP/GLP-1 agonist approved by the FDA for type 2 diabetes and obesity. Retatrutide adds a third receptor arm — glucagon — which tirzepatide does not activate. In Phase 2, the highest retatrutide dose (12 mg, 48 weeks) produced approximately 24.2% weight loss; the highest tirzepatide phase 3 dose (15 mg, 72 weeks) produced approximately 22.5% weight loss in the SURMOUNT-1 trial. Direct comparison is not valid across different trial populations and durations — the TRIUMPH program includes an active-comparator trial versus tirzepatide specifically to answer the head-to-head question. The mechanistic difference (triple vs dual agonism) is not a claim of superiority — it is a pharmacological distinction whose clinical significance will be determined by Phase 3. The 2025 Biomolecules review (Katsi et al.) characterized the weight-loss profile as a 'step-change' relative to prior incretin agents, but noted that the GI and heart-rate safety profile is the key tradeoff [6]. Key distinction: tirzepatide is approved; retatrutide is not. Use of unapproved retatrutide carries all the regulatory and safety uncertainties described in the effects and dosage pages. Retatrutide [Retatrutide references](/references) are indexed on the references page. ## Retatrutide side effects The principal adverse effects documented in Phase 2 clinical trials: **Gastrointestinal.** Nausea, vomiting, diarrhea, and constipation — dose-related, predominantly mild-to-moderate, most pronounced during dose escalation. Up to 45% of participants at the highest dose experienced nausea; the 18% discontinuation rate at 12 mg was primarily GI-driven [1]. Retatrutide delays gastric emptying, a mechanism confirmed in a 2023 study by Urva et al. [9], which underlies both the nausea and the sulfur-burp pattern widely reported in community settings. **Heart rate.** A dose-dependent increase in resting heart rate was observed in Phase 2, peaking at approximately week 24. Mean increases were approximately 5–7 bpm at the highest doses [1]. The glucagon receptor arm is the primary driver of this chronotropic (heart-rate-increasing) effect via cAMP/PKA cardiac signaling. A dedicated cardiovascular outcomes trial is ongoing. **Injection-site reactions.** Approximately 8% of Phase 2 participants reported mild local reactions at the injection site [1]. **Lean-mass reduction.** Body-composition data confirm absolute lean-mass loss alongside fat-mass loss, though the fat-to-lean ratio is more favorable than historic bariatric benchmarks [14]. **Dysesthesia (burning or tingling skin sensations).** A 2026 pharmacovigilance analysis (Laroche et al., *EJCP*) identified dysesthesia as a class-level signal for GLP-1R-based agents in the VigiBase adverse-event database — an under-recognized adverse event beyond GI symptoms [13]. --- An apothecary's specimen record of the retatrutide pharmacokinetics literature — trial findings documented to source, no dispensary behind the cabinet, no prescription filled here.